This site is intended only for healthcare professionals residing in Malaysia




Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



AboutStudy Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy managementResourcesPrescribing InformationEventsMaterialsVideos
Prescribing InformationPatient InformationIndicationPatient Site
First-line overall efficacyLORVIQUA significantly improved progression-free survival vs crizotinib1,2 Progression-free survival by BICR (ITT population, N=296)1,2

Data cutoff: 20 March 2020.2
Adapted from Shaw AT et al. N Engl J Med. 2020;383:2018-29.2

  • Patients receiving LORVIQUA experienced longer PFS vs crizotinib, irrespective of baseline patient and disease characteristics1,2
  • At data cutoff, OS data were not mature2
Progression-free survival (BICR assessed): subgroup analysis3

Data cutoff: 20 March 2020.2
Adapted from Shaw AT et al. N Engl J Med (Suppl). 2020;383:2018-29.3

This graph depicts prespecified exploratory subgroup analyses from the CROWN trial. Small patient numbers can be a limitation of subgroup analyses. These results are presented for descriptive purposes and should not be interpreted as a demonstration of efficacy in any particular subgroup.

Improved tumour response with LORVIQUA vs crizotinib1,2 ORR (ITT population, N=296)a

aDefined as confirmed complete response or partial response as assessed by BICR.1,2 
Data cutoff: 20 March 2020.2

  • Median DoR: Not estimable (95% Cl, NE-NE) with LORVIQUA vs 11 months (95% Cl, 9-13) with crizotinib1
  • Response duration ≥12 months: 70% with LORVIQUA vs 27% with crizotinib2
BICR=blinded independent central review; CNS=central nervous system; DoR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; ITT=intention to treat; NE=not estimable; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.ReferencesReferences:Lorviqua Prescribing Information. Accessed on 30 May 2023.Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer [supplementary appendix]. N Engl J Med. 2020;383(21):2018-2029.
LORVIQUA safety profile
Review the safety
First-line LORVIQUA Case Study Video

Todd Bauer, MD, presents a case study of a patient with ALK+ NSCLC receiving LORVIQUA in the first-line setting.

Go to video Loading


To view the full Prescribing Information, please click the “Prescribing Information” submenu in the Resources tab.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.


This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 

Copyright © 2023 Pfizer Limited. All rights reserved.


You are now leaving the PfizerPro Malaysia website
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
     PP-UNP-MYS-0077 - 10FEB2023